1.        Nicol AJ, Hagi T, Nicol JL, Ando Y, Juji T, Nieda M. Phase I clinical evaluation of immune therapy with dendritic cells pulsed with alpha-GalactosylCeramide (KRN7000) and tumour antigens in Stage IV metastatic melanoma. (in preparation) 

2.        Hagi T,  Valuks A, Nicol JL, Nieda M, Nicol AJ, Clinical evaluation of melanoma vaccines that co-stimulate Vgamma9Vdelta2 T cells and alpha-beta T cells following therapy to suppress regulatory T cells. (in preparation) 

3.        Nicol AJ, Tazbirkova A, Ando Y, Okai M, McFarlane D, Juji T, Abraham R, Nieda M. Phase I clinical evaluation of therapy with alpha-GalactosylCeramide (KRN7000)-pulsed dendritic cells in patients with metastatic malignancy (in preparation)

4.        Tokuyama H, Mattarollo S, Morley J, Wang Q, Fai-so H, Hagi T, Suzuki K, Nieda M, Yokokawa K, Nicol AJ. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for solid tumors (in preparation)

5.        Abe Y, Muto M, Nieda M, Nakagawa Y,  Nicol A, Kaneko T, Goto S, Yokogawa K and Suzuki K. (2009) ‘Clinical and immunological evaluation of zolendronate-activated Vgamma9Vdelta2 T cell-based immunotherapy for patients with multiple myeloma’, Experimental Hematology 37(8):956-968.

6.        Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, Moriyasu F, Nieda M &Nicol AJ. (2008), Vgamma9Vdelta2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-Rituximab and trastuzumab. International Journal of Cancer 122(11), 2526-34.

7.        Takahara M, Miyai M, Tomiyama M, Mutou M, Nicol AJ, Nieda M. (2008) Co-pulsing tumor antigen pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vγ9γδ T cell activation. Journal of Leukocyte Biology 83(3):742-54.

8.        Mattarollo S, Kenna T, Nieda M, Nicol AJ. (2007) Chemotherapy and Zoledronate sensitize solid tumor cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunology Immunotherapy 56(8):1285-97.

9.        Lickliter JD, Cox J, McCarron J, Martinez NR, Schmidt CW, Lin H, Nieda M and Nicol AJ.  (2007) Small-molecule Bcl-2 inhibitors sensitize tumour cells to immune-mediated destruction. British Journal of Cancer 96(4):600-8.

10.        Mattarollo SR, Kenna T, Nieda M and Nicol AJ. (2006) Chemotherapy pre-treatment sensitizes solid tumor-derived targets to Vα24+NKT cell-mediated cytotoxicity. International Journal of Cancer 119(7):1630-7.

11.     Lin H, Nieda M, Hutton JF, Rozenkov V and Nicol AJ. (2006) Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells and B cells. Experimental Hematology 34(3): 289-295.

12.     Lin H, Nieda M, Hutton JF, Rozenkov V and Nicol AJ. (2006) Comparative gene expression analysis of NKT cell subpopulations. Journal of Leukocyte Biology 80(1):164-73.

13.      Crough T, Purdie DM, Okai M, Maksoud A, Nieda M and Nicol AJ. (2004) Modulation of human Ca24+Vb11: NKT cells by age, malignancy and conventional anti-cancer therapies. British Journal of Cancer 91(11):1880-6.

14.      Crough T, Nieda M, Nicol AJ. (2004) Granulocyte Colony-Stimulation Factor suppresses a-Galactosyl Ceramide responsive human Ca24+Vb11+ NIKT cells and causes Th2 polarization.Journal of Immunology 173(8):4960-6.

15.      Lin H, Nieda M, Nicol AJ. (2004) Differential proliferative response of NKT Cell subpopulations to in-vitro stimulation in the presence of different cytokines.European Journal of Immunology. 34(10):2664-71.

16.      Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane D and Nicol AJ. (2004) Therapeutic activation of Vα24+Vβ11+NKT cells in human subjects results in highly co-ordinated secondary activation of acquired and innate immunity. Blood 103(2):383-389.

17.      Tazbirkova A, Maksoud A, Horley D, Okai M, Crough T, Nicol AJ. (2003) Effects of leukapheresis protocol, cell processing and cryopreservation on the generation of monocyte-derived dendritic cells for immune therapy. Cytotherapy 5(1): 31-39.

18.      Kashiwase K, Kikuchi A, Ando Y, Nicol AJ, Porcelli SA, Tokunaga K, Omine M, Satake M, Juji T, Nieda M, and Koezuka Y. (2003). The CD1d natural killer T-cell antigen presentation pathway is highly conserved between humans and rhesus macaques. Immunogenetics. 54:776-781.

19.      Henderson RD, Rajah T, Nicol AJ, Read SJ. (2003) Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology. 60(2):326-8.

20.      Clark T, Nieda M, Morton AJ, Boyd A, Bashford J, Durrant S, Nicol AJ. (2002) Donor derived b2a2-specific T cells for immunotherapy of CML. Journal of Immunotherapy  25(6):469-75.

21.      Okai M, Nieda M, Tazbirkova A, Horley D, Kikuchi A, Durrant S, Takahashi T, Abraham R, Yagita H, Juji T, Nicol AJ.(2002) Human peripheral blood Vα24+Vβ11+NKT cells expand following administration of α-Galactosylceramide-pulsed dendritic cells. Vox Sanguinis 83(3):250-3.

22.      Lapteva N, Nieda M, Ando Y, Nicol AJ, Ide K, Hatta-Ohashe Y, Egawa K, Juji T, Tokunaga K. (2001) Gene expression profiling in human monocytes, monocyte-derived dendritic cells and a-galactosylceramide-pulsed monocyte-derived dendritic cells. Biochemical and Biophysical Research Communications ;289(2):531-8.

23.      Kikuchi A., Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A. (2001) In vitro anti-tumour activity of α-Galactosyl Ceramide stimulated human invariant Va24NKT cells against melanoma. British Journal of Cancer Sep 1;85(5):741-6.

24.      Nieda M, Nicol AJ, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, Tokunaga K, Suzuki K, Kayagaki N, Yagiat H, Hirai H & Juji T. (2001) TRAIL expression by activated human CD4+ V-alpha 24+NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukaemia cells. Blood  97 2067-74.

25.      Nieda M, Kikuchi A, Nicol A, Koezuka Y, Ando Y, Ishihara S, Lapteva N, Yabe T, Tokunaga K, Tadokoro K & Juji T. (2001) Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4+Va24 natural killer T cells expressing CD40L. Immunology 102(2)137-145.

26.      Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S & Juji T. (2000)  Dendritic cells are targets for human invariant Va24+ NKT cell cytototoxic activity - an important immune regulatory function.  Experimental Hematology 28(3) 276-82. 

27.      Takahashi T, Nieda M, Koezuka Y, Nicol AJ, Porcelli S, Ishikawa Y, Tadokoro K, Hirai H & Juji T. (2000) Analysis of human Va24+ NKT cells activated by a-glycolsylceramide-pulsed monocyte derived dendritic cells. Journal of Immunology 164, 4458-4464.

28.      Nicol AJ, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S & Juji T. (2000) Human invariant Va24+ NKT cells activated by a-GalactosylCeramide (KRN7000) have cytotoxic antitumour activity through mechanisms distinct from T cells and NK cells.  Immunology,99, 229-234.

29.      Nieda M, Nicol A, Koezuka Y, Kikuchi A, Takahashi T, Nakamura H, Furukawa H, Yabe T, Ishikawa Y, Tadokoro K & Juji T. (1999) Activation of human Va24NKT cells by a-glycosylceramide in a CD1d-restricted and Va24TCR-mediated manner. Human Immunology, 60, 10-19.

30.      Denning-Kendall PA, Nicol A J, Horsley H, Donaldson C, Bradley B & Hows JM. (1998) Is in vitro expansion of human cord blood cells clinically relevant? Bone Marrow Transplantation, 21, 225-232.

31.      Denning-Kendall PA, Horsley H, Nicol A, Nieda M, Bradley B & Hows JM. (1998) Clinical application of in vitro expansion of cord blood. Bone Marrow Transplantation, 22, S63-S65.

32.      Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, Tadokoro K & Juji T. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood, 91, 977-983.

33.      Denning-Kendall P, Donaldson C, Nicol AJ, Bradley BA & Hows JM. (1996) Optimization of red cell depletion of cord blood for banking. Experimental Hematology, 24, 1394-1401.

34.      Donaldson C, Armitage WJ, Denning-Kendall PA, Nicol AJ, Bradley BA & Hows JM. (1996) Optimal cryopreservation of human umbilical cord blood (UCB). Bone Marrow Transplantation, 18, 725-731.

35.      Hows J, Nicol A, Denning-Kendall P, Donaldson C, Nieda M & Bradley B. (1996) Cord Blood as an alternate source of haemopoietic stem cells. Annals of Oncology, 7, 47-51.

36.      Nieda M, Nicol AJ, Denning-Kendall PA, Sweetenham J, Bradley B & Hows JM. (1996) Endothelial cells derived from CD34+ human umbilical cord blood cells support hematopoiesis. British Journal of Haematology, 98, 775-777.

37.      Nicol AJ, Nieda M, Donaldson C, Denning-Kendall PA, Bradley B & Hows J. (1995) Analysis of cord blood CD34+ cells purified after cryopreservation. Experimental Hematology,23, 1589-1594.

38.      Donaldson C, Denning-Kendall P, Nicol A J, Laundy G, Hows J & Bradley B. (1994) Human Cord Blood Banking: An alternative to unrelated marrow Donor Registries? European Foundation for Immunogenetics Newsletter, 20-21.

39.      Nicol A J, Hows JM & Bradley BA. (1994) Cord blood transplantation: a practical option? British Journal of Haematology, 87, 1-5.

Back to Top